Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The sequelae of Bell's palsy cause critical problem in facial appearance, as well as social and psychological problems in the patient's life. The aim of the present study is to establish clinical evidence of thread-embedding acupuncture (TEA) in the treatment of sequelae of Bell's palsy.

Method/design: This is a patient-assessor blinded, randomized, sham-controlled trial with two parallel arms. Fifty-six patients aged 19-65 years, who have experienced sequelae of Bell's palsy for >3 months, will be recruited and screened using the eligibility criteria. After screening, they will be randomly allocated to a TEA group or a sham TEA (STEA) group. Both groups will receive TEA or STEA treatment on ten predefined acupoints once a week for 8 weeks. Additionally, both groups will receive the same acupuncture treatment twice a week for 8 weeks as a concurrent treatment. Changes in the Facial Disability Index over 8 weeks will be assessed as the primary outcome. Furthermore, the House-Brackmann Grade, Facial Nerve Grading System 2.0, Sunnybrook Facial Grading System, facial stiffness score, lip mobility score, and treatment satisfaction score will be measured and analyzed as secondary outcomes. All outcomes will be assessed at baseline and at 4 and 8 weeks after screening.

Discussion: The results from this trial will help establish clinical evidence regarding the efficacy and safety of TEA in the treatment of patients with sequelae of Bell's palsy.

Trial Registration Number: KCT0002557 (Clinical Research Information Service of the Republic of Korea).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408039PMC
http://dx.doi.org/10.1097/MD.0000000000014508DOI Listing

Publication Analysis

Top Keywords

sequelae bell's
20
bell's palsy
12
efficacy safety
8
thread-embedding acupuncture
8
acupuncture treatment
8
treatment sequelae
8
patient-assessor blinded
8
blinded randomized
8
establish clinical
8
clinical evidence
8

Similar Publications

Long COVID and the kidney.

Nat Rev Nephrol

September 2025

Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.

Long coronavirus disease (COVID) - commonly defined as symptoms and/or long-term effects that persist for at least 3 months after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cannot be explained by an alternative diagnosis - is a complex, multifaceted and heterogeneous disease that affects many organ systems, including the kidney. COVID-19 can cause acute kidney injury, and several studies have reported an increased risk of chronic kidney disease (CKD) following COVID-19, suggesting that CKD can be a manifestation of long COVID. Furthermore, patients with CKD are at an increased risk of severe COVID-19 and of long COVID.

View Article and Find Full Text PDF

Introduction: Bell's palsy is the most common cause of peripheral facial paralysis, with an annual incidence of 5-50 per 100,000 cases worldwide. Its etiology remains largely unknown, though risk factors such as herpes simplex virus reactivation, diabetes, depression, and pregnancy-related complications have been suggested. Understanding these risk factors is critical for improving diagnosis, prevention, and treatment strategies.

View Article and Find Full Text PDF

Purpose: Bell's palsy is a peripheral neuropathy that requires early administration of high-dose corticosteroids as initial treatment. There is a lack of clinical evidence on the effects of herbal medicines on liver and renal function, as well as their interactions with conventional medicines. This study aimed to assess the safety of using herbal medicine and corticosteroids.

View Article and Find Full Text PDF

Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.

Lancet

August 2025

Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, ON, Canada; Department of Medicine and Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.

Background: Patients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish if spironolactone reduces heart failure and cardiovascular deaths in these patients.

Methods: ACHIEVE was an international, parallel-group, randomised controlled trial done in 143 dialysis programmes in 12 countries.

View Article and Find Full Text PDF